Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: A cohort study from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme Academic Article uri icon

Overview

MeSH Major

  • Angiotensin II Type 1 Receptor Blockers
  • Anti-Inflammatory Agents, Non-Steroidal
  • Aspirin
  • Benzimidazoles
  • Heart Failure
  • Tetrazoles

abstract

  • There appears to be no significant modification of the benefit of candesartan on CV mortality and morbidity outcomes or safety by concomitant use of aspirin in patients with chronic HF.

publication date

  • January 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/eurjhf/hfq065

PubMed ID

  • 20418272

Additional Document Info

start page

  • 738

end page

  • 45

volume

  • 12

number

  • 7